In the absence of a submission from the holder of the marketing authorisation:
glibenclamide (Amglidia®) is not recommended for use within NHSScotland.
Indication under review: Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice366KB (PDF)
- Medicine name:
- glibenclamide (Amglidia)
- SMC ID:
Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.
- Pharmaceutical company
- Amring Pharma
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 07 October 2019